Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.61 |
| ▸ | HPGD | P15428 | 3/20 | 0.54 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 7/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | RAB9A | P51151 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL672281 | 1.00 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDLMNAMAPT | |
| SCHEMBL20439669 | 0.85 | ALDH1A1 (0.61) | ALDH1A1KDM4EHPGDLMNAMAPT | |
| SCHEMBL30970409 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDLMNAMAPT | |
| SCHEMBL20474213 | 0.84 | ALDH1A1 (0.59) | ALDH1A1KDM4EHPGDLMNAMAPT | |
| SCHEMBL14314339 | 0.78 | NFE2L2 (0.54) | ALDH1A1KDM4EHPGDMAPTMEN1 | |
| SCHEMBL14070022 | 0.76 | LMNA (0.64) | ALDH1A1HPGDLMNAMAPTMEN1 | |
| SCHEMBL2486594 | 0.76 | KDM4E (1.00) | ALDH1A1KDM4EHPGDLMNAMAPT | |
| SCHEMBL2486592 | 0.76 | KDM4E (1.00) | ALDH1A1KDM4EHPGDLMNAMAPT | |
| SCHEMBL30970392 | 0.76 | ALDH1A1 (0.50) | ALDH1A1KDM4EHPGDLMNAMAPT | |
| SCHEMBL30259471 | 0.76 | KDM4E (1.00) | ALDH1A1KDM4EHPGDLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9422273-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2016-08-23 | — | — | US | disclosed |
| US-20160068520-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. | 2016-03-10 | — | — | US | disclosed |
| US-9085567-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2015-07-21 | — | — | US | disclosed |
| US-20140249192-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2014-09-04 | — | — | US | disclosed |
| EP-2606044-B1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN INC (US) | 2014-06-04 | — | — | EP | disclosed |
| EP-2699565-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS FOR TREATING PAIN | Allergan, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-8653118-B2 | Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response | ALLERGAN, INC. (US) | 2014-02-18 | — | — | US | disclosed |
| EP-2606044-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | Allergan, Inc. (US) | 2013-06-26 | — | — | EP | disclosed |
| US-20130150417-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2013-06-13 | — | — | US | disclosed |
| WO-2012145737-A1 | FATTY ACID AMIDE HYDROLASE INHIBITORS FOR TREATING | ALLERGAN, INC. (US) | 2012-10-26 | — | — | WO | disclosed |
| US-20120270915-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | ENERGY, UNITED STATES DEPARTMENT OF | 2012-10-25 | — | — | US | disclosed |
| US-20120077858-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2012-03-29 | — | — | US | disclosed |
| WO-2012024559-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | ALLERGAN, INC. (US) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077858-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER3 | ALDH1A1 2036/4885KDM4E 3170/4885HPGD 484/4885 |
| US-20120270915-A1 | FATTY ACID AMIDE HYDROLASE INHIHIBITORS FOR TREATING PAIN | FAAH, FAAH2, FAH | ALDH1A1 95/4885KDM4E 2715/4885HPGD 86/4885 |
| US-20130150417-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER3 | ALDH1A1 2310/4885KDM4E 2392/4885HPGD 508/4885 |
| US-20160068520-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER3 | ALDH1A1 2036/4885KDM4E 3170/4885HPGD 484/4885 |
| US-20140249192-A1 | COMPOUNDS ACT AT MULTIPLE PROSTAGLANDIN RECEPTORS GIVING A GENERAL ANTI-INFLAMMATORY RESPONSE | PTGER1, PTGER4, PTGER3 | ALDH1A1 2036/4885KDM4E 3170/4885HPGD 484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.